SCHEMBL3359822

SCHEMBL3359822

CC(C)(N)CC=CC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
GABRR1 P24046 2/20 0.48
GABRR2 P28476 2/20 0.48
BLM P54132 2/20 0.48
GABRR3 A8MPY1 1/20 0.48
LMNA P02545 1/20 0.48
APEX1 P27695 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
TP53 P04637 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
GABRP O00591 2/20 0.34
GABRD O14764 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRB1 P18505 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3359819 1.00 TSHR (0.48) TSHRGABRR1GABRR2BLMGABRR3
Hydrochloric Acid SCHEMBL21001952 0.98 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
Hydrochloric Acid SCHEMBL21001954 0.98 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL21521060 0.80 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL3023205 0.80 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL2467206 0.80 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL3023206 0.80 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL2467205 0.80 TSHR (0.46) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL5278328 0.79 TSHR (0.41) TSHRGABRR1GABRR2BLMGABRR3
SCHEMBL16431213 0.78 TSHR (0.44) TSHRGABRR1GABRR2BLMGABRR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077941-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2009-08-12 EP claimed
EP-0805816-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2004-07-28 EP claimed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
US-6303620-B1 USED FOR THERAPY OF MEDICAL DISORDERS RESULTING FROM A DEFICIENCY IN GROWTH HORMONE NOVO NORDISK A/S (DK) 2001-10-16 US claimed
EP-1077941-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES Novo Nordisk A/S (DK) 2001-02-28 EP claimed
EP-1060190-A1 NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE NOVO NORDISK A/S (DK) 2000-12-20 EP claimed
US-6127341-A AMINOMETHYL-N-(1-((2-(2-THIENYL)-1-(1-CARBAMOYL-5 -AMINOPENTYLCARBAMOYL)ETHYL)-N-METHYLCARBAMOYL)-2-(2 -NAPTHYL)ETHYL)BENZAMIDE, FOR EXAMPLE; ADMINISTERING TO STIMULATE GROWTH, MILK OR WOOL PRODUCTION IN ANIMALS NOVO NORDISK A/S (DK) 2000-10-03 US claimed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US claimed
EP-1005484-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 2000-06-07 EP claimed
WO-1999058501-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1999-11-18 WO claimed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US claimed
WO-1999045029-A1 NEW SALT FORMS OF (2E)- 5-AMINO-5- METHYLHEX-2- ENOIC ACID N-METHYL-N-((1R)-1-(N- METHYL-N-((1R)-1-(METHYLCARBAMOYL)-2- PHENYLETHYL)CARBAMOYL)-2- (2-NAPHTYL)ETHYL)AMIDE NOVO NORDISK A/S (DK) 1999-09-10 WO claimed
WO-1998058950-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-12-30 WO claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP claimed
EP-0805816-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-11-12 EP claimed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO claimed
WO-1996022997-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-08-01 WO claimed
EP-1789067-B8 Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system HELSINN HEALTHCARE SA (CH) 2012-08-15 EP disclosed
WO-1996022997-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 TSHR 63/4885GABRR1 924/4885GABRR2 1284/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR TSHR 65/4885GABRR1 863/4885GABRR2 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.